12 reports

WOUND CLOSURE DEVICE VASCULITUS WOUND CLOSURE DEVICE PRODUCT OVERVIEW VASCULITUS WOUND CLOSURE DEVICE - PRODUCT STATUS Market Category Developed By Pipeline Territory Highest Stage of Development Wound Care Management-->

  • Medical Device
  • Medical Equipment
  • Musculoskeletal Disorder
  • Opioid
  • PetVivo Holdings, Inc.

Many of these wound care biologics are substitutes for skin structures and promote healing and the wound closure process.

  • Cell Therapy
  • Musculoskeletal Disorder
  • North America
  • United States
  • Novartis AG

Patients were randomized to receive either a single ## mL dose of Adlea (##. ## mg/ mL drug concentration) or placebo instilled into the surgical site immediately prior to wound closure.

  • Chronic Pain
  • Musculoskeletal Disorder
  • Therapy
  • United States
  • Flex Pharma, Inc.
  • 5. All the trials included are unique trials.

Percolation of LA Directly into Wound Cavity, Prior to Wound Closure, While the Patient is under a General Anesthetic.

  • Clinical Trial
  • Musculoskeletal Disorder
  • Pharmaceutical
  • Therapy
  • World

TWO PATIENTS IN GROUP ## ACHIEVED COMPLETE CLOSURE OF THE FISTULA AT MONTH ## AND MONTH ##, AND ONE PATIENT IN GROUP ## ACHIEVED COMPLETE CLOSURE AT ## WEEKS.

  • Arthritis
  • Musculoskeletal Disorder
  • North America
  • United States
  • Can-Fite BioPharma Ltd.

Patients were randomized to receive either a single ## mL dose of Adlea (##. ## mg/ mL drug concentration) or placebo instilled into the surgical site immediately prior to wound closure.

  • Musculoskeletal Disorder
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

OVER ## DAYS, THE DIABETICS EXHIBITED IMPAIRED WOUND CLOSURE, ASSESSED BY GROSS AND HISTOLOGIC MEASUREMENTS, COMPARED TO THE NON DIABETIC CONTROLS.

  • Arthritis
  • Musculoskeletal Disorder
  • United States
  • World
  • Product Initiative

Statistical analysis between groups revealed that the wounds treated with an Excellagen-CD##+ cell treatment demonstrated increased percentage wound closure with more prominent neovasculature.

  • Musculoskeletal Disorder
  • Therapy
  • United States
  • Product Initiative
  • Pluristem Therapeutics Inc.
  • 5. All the trials included are unique trials.

Percolation of LA Directly into Wound Cavity, Prior to Wound Closure, While the Patient is under a General Anesthetic.

  • Clinical Trial
  • Musculoskeletal Disorder
  • Pharmaceutical
  • Therapy
  • World

Seventeen of the remaining ## evaluable subjects progressed to complete wound closure by ## months, the trial s second primary endpoint; one subject achieved closure after ## months due to a wound dressing error that temporarily reopened her closed

  • Autoimmune Disease
  • Monoclonal Antibody
  • Musculoskeletal Disorder
  • United States
  • Product Initiative

Following the closure of recruitment, the last patient will now be randomized in the study before the end of the month.

  • Chronic Disease
  • Musculoskeletal Disorder
  • United States
  • Company
  • Product Initiative

Patients were randomized to receive either a single ## mL dose of Adlea (##. ## mg/ mL drug concentration) or placebo instilled into the surgical site immediately prior to wound closure.

  • Musculoskeletal Disorder
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative